Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market.

Reuters • Feb 3, 2026

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The gross proceeds to the Company were approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately upon issuance and will not expire until fully exercised.

GlobeNewsWire • Jan 29, 2026

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune Inc (NASDAQ: ALT) shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.

Benzinga • Jan 28, 2026

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The offering is expected to close on or about January 29, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Jan 28, 2026

Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly

Shares of Altimmune ( NASDAQ:ALT ) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit.

24/7 Wall Street • Jan 23, 2026

ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH

Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.

Zacks Investment Research • Jan 6, 2026

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA

GlobeNewsWire • Jan 5, 2026

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

Zacks Investment Research • Dec 29, 2025

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune delivered strong 48-week Phase IIb data for pemvidutide in MASH, supporting progression to Phase III. Pemvidutide showed durable, dose-dependent improvements in non-invasive fibrosis markers and consistent safety, with weight loss reaching 7.5% at 1.8 mg. Regulatory alignment for a Phase III trial targeting accelerated approval appears promising, with biopsy-based endpoints and a planned 2.4 mg dose.

Seeking Alpha • Dec 24, 2025

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune said on Friday its experimental drug improved signs of liver scarring and liver health after 48 weeks of treatment in a mid-stage study of patients with a serious fatty liver disease known as MASH.

Reuters • Dec 19, 2025